Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Horm Behav ; 156: 105449, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37922678

RESUMEN

The present study investigated the participation of the nitric oxide pathway in facilitating lordosis behavior induced by intrahypothalamic administration of apelin-13 in ovariectomized rats primed with estradiol benzoate (EB). The experiments involved the administration of a nitric oxide synthase inhibitor (L-NAME) or a nitric oxide-dependent, soluble guanylyl cyclase inhibitor (ODQ), and an inhibitor of protein kinase G (KT5823) to the ventromedial hypothalamus (VMH) of EB-primed rats 30 min before infusion of apelin-13 (0.75 µg/µl). This dose of apelin-13 consistently induces lordosis behavior at 30 min, 120 min, and 240 min following infusion. Results showed that injections of either L-NAME or KT5823 significantly reduced the lordosis induced by apelin at 120 and 240 min. However, VMH infusion of ODQ 30 min before apelin-13 infusion reduced but did not significantly inhibit, the lordosis elicited by this peptide at the same time points. We conclude that the nitric oxide pathway in the VMH plays an important role in lordosis induced by apelin-13 in EB-primed rats.


Asunto(s)
Lordosis , Óxido Nítrico , Ratas , Femenino , Animales , NG-Nitroarginina Metil Éster/farmacología , Óxido Nítrico/metabolismo , Lordosis/inducido químicamente , Conducta Sexual Animal/fisiología , Estradiol/farmacología
2.
Neurosci Lett ; 773: 136518, 2022 03 16.
Artículo en Inglés | MEDLINE | ID: mdl-35150776

RESUMEN

In normal hormonal conditions, increased neuronal activity in the ventromedial hypothalamus (VMH) induces lordosis whereas activation of the preoptic area (POA) exerts an opposite effect. In the present work, we explored the effect of bilateral infusion of different doses of the apelin-13 (0.37, 0.75, 1.5, and 15 µg) in both brain areas on the expression of lordosis behavior. Lordosis quotient and lordosis reflex score were performed at 30, 120, and 240 min. Weak lordosis was observed following the 0.37 µg dose of apelin-13 at 30 min in the VMH of EB-primed rats; however, the rest of the doses induced significant lordosis relative to the control group. At 120 min, all doses induced lordosis behavior, while at 240 min, the highest dose of 15 µg did not induce significant differences. Interestingly, only the 0.75 µg infusion of apelin in the POA induced significant lordosis at 120 and 240 min. These results indicate that apelin-13 acts preferably in HVM and slightly in POA to initiate lordosis behavior in estrogen-primed rats.


Asunto(s)
Péptidos y Proteínas de Señalización Intercelular , Lordosis , Área Preóptica , Animales , Estradiol/farmacología , Estrógenos/farmacología , Hipotálamo/efectos de los fármacos , Hipotálamo/patología , Péptidos y Proteínas de Señalización Intercelular/farmacología , Lordosis/inducido químicamente , Área Preóptica/efectos de los fármacos , Área Preóptica/patología , Progesterona/farmacología , Ratas , Conducta Sexual Animal/efectos de los fármacos , Núcleo Hipotalámico Ventromedial/efectos de los fármacos , Núcleo Hipotalámico Ventromedial/patología
3.
Horm Behav ; 136: 105081, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34710777

RESUMEN

Intracerebroventricular (icv) administration of oxytocin (OT) induces robust lordosis behavior (lordosis quotient and lordosis intensity) in estrogen-primed rats. The present study explored the hypothesis that the OT-Prostaglandin E2-GnRH pathway (a pathway produced in astrocytes) is involved in the facilitation of lordosis behavior by icv infusion of OT (2 µg). In Experiment 1, we tested the involvement of the OT receptor (OTR) by infusion of the OTR antagonist, atosiban (ATO). OT-induced lordosis was significantly reduced at both 30 and 120 min by prior infusion of ATO. In Experiment 2, we studied the effects of aspirin (COX2 inhibitor) and ONO-AE3-208 (ONO; EP4 prostaglandin receptor antagonist) on OT-induced lordosis. Infusions of both compounds diminished OT-induced lordosis at both 120 and 240 min. In Experiment 3, the involvement of the GnRH-1 receptor inhibitor antide on OT-induced lordosis was evaluated. Antide significantly inhibited OT-induced lordosis at all times tested. These data indicate that the OT/PGE2/GnRH pathway is involved in the expression of OT-induced lordosis behavior, an effect that may be occurring directly in hypothalamic astrocytes.


Asunto(s)
Dinoprostona , Lordosis , Animales , Dinoprostona/farmacología , Femenino , Hormona Liberadora de Gonadotropina/metabolismo , Hormona Liberadora de Gonadotropina/farmacología , Lordosis/inducido químicamente , Oxitocina/farmacología , Ratas , Ratas Sprague-Dawley , Conducta Sexual Animal
4.
J Neuroendocrinol ; 31(12): e12809, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31715031

RESUMEN

An injection of unesterified oestradiol (E2 ) facilitates receptive behaviour in E2 benzoate (EB)-primed, ovariectomised female rats when it is administered i.c.v. or systemically. The present study tested the hypothesis that inhibitors of protein kinase A (PKA), protein kinase G (PKG) or the Src/mitogen-activated protein kinase (MAPK) complex interfere with E2 facilitation of receptive behaviour. In Experiment 1, lordosis induced by i.c.v. infusion of E2 was significantly reduced by i.c.v. administration of Rp-cAMPS, a PKA inhibitor, KT5823, a PKG inhibitor, and PP2 and PD98059, Src and MAPK inhibitors, respectively, between 30 and 240 minutes after infusion. In Experiment 2, we determined whether the ventromedial hypothalamus (VMH) is one of the neural sites at which those intracellular pathways participate in lordosis behaviour induced by E2 . Administration of each of the four protein kinase inhibitors into the VMH blocked facilitation of lordosis induced by infusion of E2 also into the VMH. These data support the hypothesis that activation of several protein kinase pathways is involved in the facilitation of lordosis by E2 in EB-primed rats.


Asunto(s)
Antagonistas de Estrógenos/farmacología , Lordosis/fisiopatología , Inhibidores de Proteínas Quinasas/farmacología , Núcleo Hipotalámico Ventromedial/fisiología , Animales , Carbazoles/farmacología , AMP Cíclico/análogos & derivados , AMP Cíclico/farmacología , Estradiol/fisiología , Femenino , Flavonoides/farmacología , Infusiones Intraventriculares , Lordosis/inducido químicamente , Masculino , Microinyecciones , Inhibidores de Proteínas Quinasas/administración & dosificación , Pirimidinas/farmacología , Ratas , Tionucleótidos/farmacología , Núcleo Hipotalámico Ventromedial/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA